Alnylam Pharmaceuticals
Chelsea Quenneville is a highly skilled scientific professional with extensive experience in molecular and cell biology, particularly in RNA interference (RNAi) therapy validation and assay development. Currently serving as a Principal Associate Scientist at Alnylam Pharmaceuticals since December 2018, Chelsea specializes in validating genetic targets for RNAi therapies and developing various protein detection assays. Prior experience includes significant roles at Novartis Institutes for BioMedical Research, Vericel Corporation, and Swift Biosciences, where Chelsea honed expertise in next-generation sequencing, mammalian cell culture, and assay development. Chelsea holds a Master of Science degree from Brandeis University and a Bachelor of Science degree from Michigan State University, both in relevant scientific disciplines.
Alnylam Pharmaceuticals
32 followers
Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market.